New burn treatment cP12 enters early human testing
NCT ID NCT06814717
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a single dose of a new drug called cP12 in 6 adults with thermal burns covering up to 10% of their body. The main goal is to check if the drug is safe and how the body processes it. Researchers will also monitor pain and burn healing for two weeks after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THERMAL BURN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medstar Washington Hospital Center
RECRUITINGWashington D.C., District of Columbia, 20010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antidepressant cream stop Burn-Induced cellular 'Debris'?
- Can a common antidepressant calm burn damage? early study investigates
- Can a special exercise program help burn survivors walk again?
- Can plasma given right away save more burn victims?
- Can vitamin c save burn victims? major trial halted midway